GNH USA

Europe — EMA

Klertis

GNH USA supplies Klertis (Sunitinib), a tyrosine kinase inhibitor for renal cell carcinoma and gastrointestinal stromal tumor. Request a quote for supply.

Sunitinib

Request sourcing

1
Pack/s

What is Sunitinib?

Sunitinib, the active ingredient in Klertis, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for certain advanced cancers, notably renal cell carcinoma and gastrointestinal stromal tumor, in adult patients.

GNH USA supplies Klertis as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Sunitinib used for?

Klertis (sunitinib) targets receptor tyrosine kinases involved in tumor growth and angiogenesis, making it useful in specific solid‑tumor indications.

Renal cell carcinoma: slows disease progression and improves progression‑free survival. Gastrointestinal stromal tumor: inhibits tumor growth and reduces disease burden. Advanced renal cell carcinoma: extends progression‑free survival in patients with metastatic disease.

What are the side effects of Sunitinib?

Sunitinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue - Nausea - Hypertension - Diarrhea

Serious or Rare Side Effects: - Cardiac dysfunction (e.g., reduced ejection fraction) - Severe hepatic toxicity - Thromboembolic events (e.g., deep‑vein thrombosis)

What precautions apply to Sunitinib?

When prescribing or dispensing Klertis, consider the following safety measures.

Monitor blood pressure: check regularly and manage hypertension promptly. Assess liver function: perform baseline and periodic hepatic enzyme tests. Evaluate cardiac status: obtain baseline ECG and monitor for signs of heart failure. Review concomitant medications: avoid drugs that strongly affect CYP3A4 metabolism. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

What does Sunitinib interact with?

Sunitinib interacts with several drug classes; awareness helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) - Concurrent use with other tyrosine‑kinase inhibitors

Moderate Interactions (Monitor Closely): - Antihypertensive agents (dose adjustments may be needed) - Warfarin or other anticoagulants (monitor INR closely) - CYP2C8 substrates (e.g., paclitaxel) – watch for altered plasma levels

Frequently asked questions

What conditions is Klertis used to treat?+
Klertis (sunitinib) is prescribed for adult patients with renal cell carcinoma and gastrointestinal stromal tumor. In both indications it works by inhibiting key signaling pathways that drive tumor growth and blood‑vessel formation, helping to control disease progression.
How does sunitinib work in the body?+
Sunitinib blocks several receptor tyrosine kinases such as VEGFR, PDGFR, KIT and FLT3. By inhibiting these receptors it reduces angiogenesis, limits cell proliferation, and promotes cancer‑cell apoptosis, thereby slowing tumor development.
What is the usual dose of Klertis?+
The dosage of Klertis is individualized by the treating physician based on the patient’s condition, weight, renal function and tolerability. Only a qualified prescriber can determine the appropriate dosing schedule.
Is Klertis safe to use during pregnancy or breastfeeding?+
Safety data for sunitinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy and while breastfeeding unless the potential benefit justifies the potential risk to the infant. Consultation with a healthcare professional is essential.
How do I order Klertis from GNH USA?+
To request Klertis, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Klertis compare with other tyrosine‑kinase inhibitors?+
Klertis (sunitinib) targets a broader spectrum of kinases, including VEGFR, PDGFR, KIT and FLT3, whereas some alternatives focus on a narrower set. This broader inhibition can offer efficacy in multiple tumor types but may also be associated with a distinct safety profile that requires careful monitoring.
What are the recommended storage conditions for Klertis?+
Klertis should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency.
How is Klertis administered to patients?+
Klertis is taken orally, usually as a whole tablet swallowed with water. The exact timing (e.g., with or without food) and dosing interval are determined by the prescribing clinician based on the therapeutic plan.
What are the most serious risks associated with Klertis?+
Serious risks include cardiac dysfunction, severe hypertension, hepatic toxicity, and thromboembolic events. Patients should be monitored regularly for signs of heart failure, liver enzyme elevations, blood‑pressure spikes and clotting complications.
Who should not use Klertis?+
Klertis is contraindicated in patients with known hypersensitivity to sunitinib or any of its excipients, and in those with uncontrolled hypertension or severe hepatic impairment. Caution is also advised for individuals taking strong CYP3A4 inhibitors or inducers.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Sunitinib
Route
Oral Use
Manufacturer
Egis Pharmaceuticals Plc
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU